The role of the brain natriuretic peptide gene polymorphism in the diagnostic use of the biomarker in myocardial dysfunction in men, residents of Podillya with comorbid essential hypertension and type 2 diabetes mellitus

  • Ya. O. Antoniuk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • A. F. Gumeniuk National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • O. O. Sakovych National Pirogov Memorial Medical University, Vinnytsya, Ukraine
  • V. M. Zhebel National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: essential hypertension, type 2 diabetes mellitus, diastolic dysfunction, the brain natriuretic peptide gene polymorphism.

Abstract

There is a growing interest in the early detection of signs of myocardial dysfunction, especially in comorbid patients for timely prevention of progression of disease, reducing the risk of complications, improving their quality of life. The aim of the work was to optimize the diagnosis of myocardial dysfunction in men, residents of Podillya, taking into account the plasma concentration of brain natriuretic peptide (BNP) and polymorphism of the corresponding gene under conditions of comorbidity of essential hypertension (EH) with left ventricular hypertrophy (LVH) and type 2 diabetes mellitus (T2D). We examined 211 men: 79 persons without the signs of cardiovascular diseases, 62 patients with EH 2 and chronic heart failure (CHF) 0-I functional classes (FC) according to NYHA Classification and 70 – with EH 2 combined with T2D and CHF FC I-II. The examination included the determination of plasma concentration of BNP, the brain natriuretic peptide gene polymorphism (polymorphic locus T-381C), indices of doppler-echocardiography. The mathematical processing was performed using the standard statistical package Statistica 10. During the study, we calculated the primary statistical indicators, identified differences between groups on statistical grounds, made correlation and discriminant analysis. Diastolic dysfunction (DD) of the left ventricle (LV) was diagnosed in 45.16% of patients in the group with EH 2, and 90% in the group of comorbid patients. It was determined that men, residents of Podillya, with presence and absence of T2D, have dominating T381C genotype of the BNP gene (p>0.05). Lower plasma concentration of BNP that is peculiar for homozygous T381T genotype, in comparison with carriers of allele C of BNP gene and the average values of this biomarker in patients with DD may affect its informativeness in the diagnosis of myocardial dysfunction and requires a lower level of diagnosis. Appropriate borderline levels of BNP were determined for early diagnosis of DD in carriers of polymorphic variants of the BNP gene in men, residents of Podillya, with comorbid course of EH 2 and T2D. It is recommended to determine the genotype of the corresponding gene (polymorphic locus T-381C) and plasma level of BNP and focus on the calculated borderline levels of BNP to optimize the diagnosis of myocardial dysfunction in comorbid patients with EH 2 and T2D. For carriers of the T381T genotype it is ≥55.57 pg/ml, for carriers of the C allele (heterozygous T381C and homozygous C381C) of the BNP gene it is ≥69.13 pg/ml.

References

[1] Al-Ibrahimi, A. S., Al-Gazally, M. E., & Alshok, M. M. (2016). Effect of natriuretic peptides (BNP) gene T-381C polymorphism on the levels of BNP and NT-proBNP in patients with cardiovascular disease. International Journal of PharmTech Research, 9(12), 223-229.
[2] Antoniuk, Ya. O., Humeniuk, A. F., Pashkova, Yu. P., Sakovych, O. O., & Zhebel, V. M. (2020). Діагностична цінність визначення мозкового натрійуретичного пептиду за коморбідного перебігу гіпертонічної хвороби та цукрового діабету 2 типу в чоловіків [The diagnostic value of brain natriuretic peptide in men with comorbid essential arterial hypertension and type 2 diabetes mellitus]. Запорожский медицинский журнал – Zaporozhye medical journal, 22(5), 627-636. doi: 10.14739/2310-1210.2020.5.214729
[3] Berezikova, E. N., Mayanskaya, S. D., Garaeva, L. A., Shilov, S. N., Efremov, A. V., Teplyakov, A. T., … & Torim, Y. Y. (2013). Полиморфизм гена мозгового натрийуретического пептида у больных с хронической сердечной недостаточностью [Brain natriuretic peptide gene polymorphism in patients with congestive heart failure]. Казанский медицинский журнал – Kazan Medical Journal, 94(4), 433-438. doi: 10.17816/kmj1944
[4] Berezin, A. E. (2017). Современная стратегия использования биологических маркеров в диагностике и стратификации пациентов с острой и хронической сердечной недостаточностью [A modern strategy for the use of biological markers in the diagnosis and stratification of patients with acute and chronic heart failure]. Серцева недостатність та коморбідні стани – Sertseva nedostatnist ta komorbidni stany, 3, 12-23.
[5] Berezin, A. E., & Berezin, A. A. (2020). Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification – A Narrative Review. Diabetes Therapy, 11(6), 1271-1291. doi: 10.1007/s13300-020-00835-9
[6] Bilovol, O. M., Bobronnikova, L. R., & Al-Trawneh, O. V. (2017). Патогенетические особенности сочетанного течения артериальной гипертензии и сахарного диабета 2 типа [Pathogenetic features of the combined course of arterial hypertension and diabetes mellitus 2 type]. Східноєвропейський журнал внутрішньої та сімейної медицини – Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini, 1, 4-9. doi: 10.15407/internalmed2017.01.004
[7] Cecelja, M., & Chowienczyk, P. (2016). Molecular Mechanisms of Arterial Stiffening. Pulse, 4(1), 43-48. doi: 10.1159/000446399
[8] Cefalu, W. T., Bakris, G., Blonde, L., Andrew J. M., D’Alessio, D., Golden, S. H., … & Wong, T. Y. (2016). Standards of medical care in diabetes – 2016. Diabetes Care, 39(1), 1-109.
[9] Clerico, A., Masotti, S., Musetti, V., & Passino, C. (2019). Pathophysiological mechanisms determining sex differences in circulating levels of cardiac natriuretic peptides and cardiac troponins. Journal Of Laboratory And Precision Medicine, 4, 8-8. doi: 10.21037/jlpm.2019.01.03
[10] Costello-Boerrigter, L. C., Boerrigter, G., Ameenuddin, S., Mahoney, D. W., Slusser, J. P., Heublein, D. M., … Burnett, J. C. (2011). The Effect of the Brain-Type Natriuretic Peptide Single-Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays. Mayo Clinic Proceedings, 86(3), 210-218. doi: 10.4065/mcp.2010.0708
[11] Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., … & PiÑa, I. L. (2019). Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. Journal of Cardiac Failure, 25(8), 584-619. doi: 10.1016/j.cardfail.2019.05.007
[12] Estel, C., & Conti, C. R. (2016). Global Burden of Cardiovascular Disease. Cardiovascular Innovations and Applications, 1(4), 369-377. doi: 10.15212/cvia.2016.0029
[13] Grigorescu, E. D., Lacatusu, C. M., Floria, M., Mihai, B. M., Cretu, I., & Sorodoc, L. (2019). Left Ventricular Diastolic Dysfunction in Type 2 Diabetes – Progress and Perspectives. Diagnostics, 9(3), 121. doi: 10.3390/diagnostics9030121
[14] Kovalenko, V. M., Sychov, O. S., Dolzhenko, M. M., Ivaniv, Yu. A., Deiak, S. I., Potashev, S. V., & Nosenko, N. M. (2016). Рекомендації з ехокардіографічної оцінки діастолічної функції лівого шлуночка [Recommendations for echocardiographic evaluation of left ventricular diastolic function]. Рекомендації робочої групи з функціональної діагностики Асоціації кардіологів України та Всеукраїнської асоціації фахівців з ехокардіографії, Київ – The recommendations of the working group of functional diagnostics Association’s of Cardiologists of Ukraine and the Ukrainian Association of Echocardiography, Kyiv.
[15] Lanfear, D. E. (2008). Genetic variation in the natriuretic peptide system and heart failure. Heart Failure Reviews, 15(3), 219-228. doi: 10.1007/s10741-008-9113-y
[16] Marwick, T. H., Ritchie, R., Shaw, J. E., & Kaye, D. (2018). Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. Journal of the American College of Cardiology, 71(3), 339-351. doi: 10.1016/j.jacc.2017.11.019
[17] Meirhaeghe, A., Sandhu, M. S., McCarthy, M. I., de Groote, P., Cottel, D., Arveiler, D., … & Amouyel, P. (2007). Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Human Molecular Genetics, 16(11), 1343-1350. doi: 10.1093/hmg/ddm084
[18] Ministry of Health of Ukraine (2012). Уніфікований клінічний протокол первинної та вторинної (спеціалізованої) медичної допомоги: цукровий діабет 2 типу [Unified clinical protocol of primary and secondary (specialized) medical care "Type 2 diabetes mellitus"]. Наказ МОЗ № 1118 від 21.12.2012 – Order of the Ministry of Health 21.12.2012 № 1118.
[19] Mueller, C., McDonald, K., de Boer, R. A., Maisel, A., Cleland, J. G. F., Kozhuharov, N., … & Januzzi, J. L. (2019). Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure, 21(6), 715-731. doi: 10.1002/ejhf.1494
[20] Nicholson, K., Makovski, T. T., Griffith, L. E., Raina, P., Stranges, S., & van den Akker, M. (2019). Multimorbidity and comorbidity revisited: refining the concepts for international health research. Journal of Clinical Epidemiology, 105, 142-146. doi: 10.1016/j.jclinepi.2018.09.008
[21] Oganov, R. G., Denisov, I. N., Simanenkov, V. I., Bakulin, I. G., Bakulina, N. V., Boldueva, S. A., … & Shalnova, S. A. (2017). Коморбидная патология в клинической практике. Клинические рекомендации [Comorbidities in practice. Clinical guidelines]. Кардиоваскулярная терапия и профилактика – Cardiovascular Therapy and Prevention, 16(6), 5-56. doi: 10.15829/1728-8800-2017-6-5-56
[22] Pashkova, Yu. P., Zhebel, N. V., Antomonov, M. Yu., Sakovych, O. O., Starzhynska, O. L., Zhebel, V. M., … & Syvak, V. H. (2016). Спосіб прогнозування ризику розвитку хронічної серцевої недостатності на тлі гіпертонічної хвороби у чоловіків 40-60 років [Method for predicting risk of chronic heart failure against hypertension in men of 40-60 years]. Патент UA 112123 Україна – Ukraine Patent UA 112123.
[23] Pashkova, І. P., Zhebel, V. M., Palahniuk, H. O., Sakovych, O. O., Starzhynska, O. L., Gumenyuk, A. F., … & Zhebel, N. V. (2015). The BNP gene polymorphism as a regulator of brain natriuretic peptide plasma level in men with uncomplicated essential hypertension and left ventricular hypertrophy. Biological Markers and Guided Therapy, 2, 13-23. doi: 10.12988/bmgt.2015.5101
[24] Pfister, R., Luben, R. N., Khaw, K. T., & Wareham, N. J. (2013). Common genetic variants of the natriuretic peptide gene locus are not associated with heart failure risk in participants in the EPIC-Norfolk study. European Journal of Heart Failure, 15(6), 624-627. doi: 10.1093/eurjhf/hft007
[25] Pfister, R., Sharp, S., Luben, R., Welsh, P., Barroso, I., Salomaa, V., … & Wareham, N. J. (2011). Mendelian Randomization Study of B-Type Natriuretic Peptide and Type 2 Diabetes: Evidence of Causal Association from Population Studies. PLoS Medicine, 8(10), e1001112. doi: 10.1371/journal.pmed.1001112
[26] Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., … & van der Meer, P. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129-2200. doi: 10.1093/eurheartj/ehw128
[27] Redfield, M. M., Rodeheffer, R. J., Jacobsen, S. J., Mahoney, D. W., Bailey, K. R., & Burnett, J. C. (2002). Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American College of Cardiology, 40(5), 976-982. doi: 10.1016/s0735-1097(02)02059-4
[28] Romano, S., Di Mauro, M., Fratini, S., Guarracini, L., Guarracini, F., Poccia, G., & Penco, M. (2010). Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovascular Diabetology, 9(1), 89. doi: 10.1186/1475-2840-9-89
[29] Seferovic, P. M., Ponikowski, P., Anker, S. D., Bauersachs, J., Chioncel, O., Cleland, J. G. F., … & Coats, A. J. S. (2019). Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 21(10), 1169-1186. doi: 10.1002/ejhf.1531
[30] Takeishi, Y., Toriyama, S., Takabatake, N., Shibata, Y., Konta, T., Emi, M., … & Kubota, I. (2007). Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochemical and Biophysical Research Communications, 362(2), 480-484. doi: 10.1016/j.bbrc.2007.08.028
[31] Tanase, D. M., Radu, S., Al Shurbaji, S., Baroi, G. L., Florida Costea, C., Turliuc, M. D., … & Floria, M. (2019). Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications. International Journal of Molecular Sciences, 20(11), 2629. doi: 10.3390/ijms20112629
[32] Voronkov, L. G., Berezin, O. E., Zharinova, V. Yu., Zhebel, V. M., Koval, O. A., Rudyk, Yu. S., … & Tseluiko, V. Y. (2019). Біологічні маркери та їх застосування при серцевій недостатності. Консенсус Всеукраїнської асоціації кардіологів України, Всеукраїнської асоціації фахівців із серцевої недостатності та Української асоціації фахівців з невідкладної кардіології [Biological markers and their use in heart failure. Consensus of Ukrainian Association of Cardiology, Ukrainian Heart Failure Association and Ukrainian Association on Acute Cardiovascular Care]. Український кардіологічний журнал – Ukrainskyi kardiolohichnyi zhurnal, 26(2), 11-22. doi: 10.31928/1608-635X-2019.2.1122
[33] Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., … & Brady, A. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39(33), 3021-3104. doi: 10.1093/eurheartj/ehy339
[34] Wu, Z., Xu, M., Sheng, H., Lou, Y., Su, X., Chen, Y., … & Jin, W. (2014). Association of natriuretic peptide polymorphisms with left ventricular dysfunction in southern Han Chinese coronary artery disease patients. International Journal of Clinical and Experimental Pathology, 7(10), 7148-7157. PMID: 25400811
[35] Yunkerov, V. I., & Grigoriev, S. G. (2002). Математико-статистическая обработка данных медицинских исследований [Mathematical and statistical processing of medical research data]. СПб: ВМедА – St. Petersburg: Voenno-med. akad.
Published
2020-09-30
How to Cite
Antoniuk, Y. O., Gumeniuk, A. F., Sakovych, O. O., & Zhebel, V. M. (2020). The role of the brain natriuretic peptide gene polymorphism in the diagnostic use of the biomarker in myocardial dysfunction in men, residents of Podillya with comorbid essential hypertension and type 2 diabetes mellitus. Biomedical and Biosocial Anthropology, (38), 54-60. https://doi.org/10.31393/bba38-2020-08